Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Show more
111 S. Wood Avenue, Building F, Suite 320, Iselin, NJ, 08830, United States
Start AI Chat
Market Cap
29.4M
52 Wk Range
$0.38 - $3.39
Previous Close
$0.40
Open
$0.41
Volume
667,713
Day Range
$0.40 - $0.43
Enterprise Value
123.4M
Cash
8.083M
Avg Qtr Burn
-12.38M
Insider Ownership
18.45%
Institutional Own.
8.22%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Wet age-related macular degeneration (AMD) | BLA FDA meeting |